ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Food Hypersensitivity
Hypersensitivity
Psoriasis
Allergic Rhinitis

Eczema trials near Berlin, BE, DEU:

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema...

Active, not recruiting
Hand Eczema
Drug: Ruxolitinib cream
Drug: Vehicle

Phase 2

Incyte
Incyte

Mahlow, Germany and 35 other locations

The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adu...

Enrolling
Eczema
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Almirall
Almirall

Berlin, Germany and 32 other locations

The purpose of this study is to assess the safety, tolerability, drug levels, drug effects, and impact on disease severity of BMS-986326 in participa...

Enrolling
Dermatitis, Atopic
Other: Placebo
Drug: BMS-986326

Phase 1

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Berlin, BE, Germany and 11 other locations

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Enrolling
Atopic Dermatitis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

Phase 3

Incyte
Incyte

Berlin, Germany and 103 other locations

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK10...

Enrolling
Dermatitis, Atopic
Drug: GSK1070806
Drug: Placebo

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Berlin, Germany and 95 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Berlin, Germany and 558 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Berlin, Germany and 320 other locations

The main purpose of the study is to assess the long-term tolerability and effectiveness of lebrikizumab in adult and adolescent participants with mod...

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Almirall
Almirall

Berlin, Germany and 31 other locations

In this study, it will be investigated if symptoms of atopic dermatitis of children with high familial risk will be delayed beyond the 6th or even 12...

Enrolling
Atopic Dermatitis
Infant, Newborn
Drug: SanaCutan Basiscreme

Phase 3

InfectoPharm

Berlin, Germany and 9 other locations

This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 3-arm study in adult participants with moderate to se...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: SAR444656 (KT-474)

Phase 2

Sanofi
Sanofi

Berlin, Germany and 24 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems